Myocarditis in a 47-Year-Old Man with Myasthenia Gravis and Malignant Thymoma Following the Administration of a Tyrosine Kinase/CDK Inhibitor

Conor McDonald, Jonathan Wackett, Steve Philpot and Benjamin M Brady
Additional contact information
Steve Philpot: Monash University, Melbourne, Australia
Benjamin M Brady: Department of Hematology and Oncology, Cabrini Hospital, Melbourne, Australia

Cancer Therapy & Oncology International Journal, 2020, vol. 16, issue 3, 45-48

Abstract: A 47-year-old man was admitted to an intensive care unit for increasing respiratory distress, persistent diarrhoea and general decline on a background of longstanding myasthenia gravis and metastatic thymic carcinoma. He had recently been involved in a phase 1 clinical trial with the drug FN-1501- an inhibitor of cyclin dependent kinases CDK2/CDK4/CDK6 and tyrosine kinase (TK) FLT3. The patient was found to have severe systolic dysfunction on echocardiography, consistent with myocarditis, for which he required inotropic support. It was only partially responsive to steroid treatment. In combination with the patient’s myasthenia gravis and deconditioning, the myocarditis contributed to the patient’s continued decline and ultimate death. This case explores the possibility that the patient’s myocardial injury and subsequent death was related to the trial drug FN-1501. An association between TK inhibitors and cardiotoxicity has been outlined in the past but the cardiac effects of CDK inhibitors is still in question. There is no data presently implicating FN-1501.

Keywords: juniper publishers:oncology journals; oncology research journals; oncology journal articles; oncology and cancer case reports; oncology journal of clinical and experimental cancer research; open access; open access journals; Oncology International Journal; juniper publishers reivew (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/ctoij/pdf/CTOIJ.MS.ID.555937.pdf (application/pdf)
https://juniperpublishers.com/ctoij/CTOIJ.MS.ID.555937.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jctoij:v:16:y:2020:i:3:p:45-48

DOI: 10.19080/CTOIJ.2020.16.555937

Access Statistics for this article

Cancer Therapy & Oncology International Journal is currently edited by Sophia Mathis

More articles in Cancer Therapy & Oncology International Journal from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().